Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come

Core Insights - Ligand Pharmaceuticals (LGND) has experienced a significant stock price increase of approximately 75% since the last article published in June 2025, which rated the company as a "Buy" [1] Company Overview - The company operates under a royalty model that is considered attractive and is driving its growth forward [1] - The author has focused research on healthcare stocks for about five years, indicating a specialization in this sector [1] Investment Philosophy - The investment approach is viewed as a learning process, where both successes and failures contribute to the overall understanding of the market [1] - The author emphasizes the importance of sharing experiences and insights with the investment community [1]